Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:15 August 2023

InMIND: This Phase III trial is evaluating the effectiveness of targeted therapy (tafasitamab), compared with a placebo, is when combined with other cancer drugs (lenalidomide and rituximab) in people with relapsed or refractory follicular lymphoma or marginal zone lymphomaA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

This is a randomised, double blind trial with an experimental and a placebo comparator arm. Participants in the Experimental arm will receive tafasitamab + rituximab + lenalidomide. Tafasitamab will be administered intravenously (IV) for 12 cycles. Rituximab will be administered via IV on cycles 1-5. Lenalidomide will be administered orally for 12 cycles. Participants in the Placebo Comparator arm will receive placebo + rituximab + lenalidomide. The Placebo will be administered via IV for 12 cycles. Rituximab will be administered via IV on cycles 1-5. Lenalidomide will be administered orally for 12 cycles.

Age

People 18+

Phase

III

Trial Acronym

InMIND

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT04680052
INCMOR0208-301; CT1419

Commercial Sponsor

Incyte Corporation

Scientific Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

Share with email

Print this page

Download brochure

Eligibility

Inclusion

You have certain types of non-cancer medical conditions.
You have been diagnosed with a prior or secondary type of cancer.
You have had certain treatments, surgical procedures or drugs.

Exclusion

You are able to swallow medication by mouth.
You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You have had treatment, but your cancer has come back.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

Information Tell us if you find this trial availability is not accurate.Report inaccuracy